Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;144(3):515-523.
doi: 10.1016/j.ygyno.2016.12.012. Epub 2016 Dec 23.

Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer

Koji Matsuo  1 , Hiroko Machida  2 , Omar M Ragab  3 , Tsuyoshi Takiuchi  2 , Huyen Q Pham  4 , Lynda D Roman  4
Affiliations

Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer

Koji Matsuo et al. Gynecol Oncol. 2017 Mar.

Abstract

Objective: To examine trends of adjuvant radiotherapy choice and to examine associations between pelvic lymphadenectomy and radiotherapy choice for women with early-stage endometrial cancer.

Methods: The Surveillance, Epidemiology, and End Results Program was used to identify surgically treated stage I-II endometrial cancer between 1983 and 2012 (type 1 n=79,474, and type 2 n=25,020). Piecewise linear regression models were used to examine temporal trends of intracavitary brachytherapy (ICBT) and whole pelvic radiotherapy (WPRT) use, pelvic lymphadenectomy rate, and sampled node counts. Multivariable binary logistic regression models were used to identify independent predictors for ICBT use.

Results: There was a significant increase in ICBT use and decrease in WPRT use during the study period. ICBT use exceeded WPRT use in 2003 for type 1 stage IA, and in 2007 for type 1 stage IB and type 2 stage IA diseases. In addition, number of sampled pelvic nodes significantly increased over time in type 1-2 stage I-II diseases (mean, 7.0-12.7 in 1988 to 15.2-17.6 in 2012, all P<0.001). On multivariable analysis, extent of sampled pelvic nodes was significantly associated with ICBT use for type 1 cancer: adjusted-odds ratios for 1-10 and >10 nodes versus no lymphadenectomy in stage IA (1.38/2.40), IB (2.75/6.32), and II (1.36/2.91) diseases. Similar trends were observed for type 2 cancer: adjusted-odds ratios for stage IA (1.69/3.73), IB (2.25/5.65), and II (1.36/2.19) diseases.

Conclusion: Our results suggest that surgeons and radiation oncologists are evaluating the extent of pelvic lymphadenectomy when counseling women with early-stage endometrial cancer for adjuvant radiotherapy.

Keywords: Adjuvant radiotherapy; Early stage; Endometrial cancer; Intracavitary brachytherapy; Whole pelvic radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement

There is no conflict of interest in all authors.

Figures

Fig. 1.
Fig. 1.
Selection schema. Abbreviations; EMCA, endometrial cancer; NOS, not otherwise specified; and LND, lymphadenectomy.
Fig. 2.
Fig. 2.
Temporal trends in treatment patterns for stage I-II endometrial cancer. Frequency of pelvic lymphadenectomy (LND, yellow line), intracavitary brachytherapy (ICBT, red line), and whole pelvic radiotherapy (WPRT, blue line) is shown for A) type I stage IA, B) type 1 stage IB, C) type I stage II, D) type II stage IA, E) type II stage IB, and F) type II stage II disease. Dots represent percent proportion with 95% confidence interval.
Fig. 3.
Fig. 3.
Trends in performance of pelvic lymphadenectomy for stage I-II endometrial cancer. Annual percent changes are: A) 1.7 (95%CI 1.4–1.9, P < 0.001), B) 5.2 between 1988 and 1999 (95%CI 3.3–7.1, P < 0.001) and 1.8 (95%CI 1.3–2.3, P < 0.001), C) 2.1 (95%CI 1.4–2.8, P < 0.001), D) 1.9 (95%CI 1.6–2.2, P < 0.001), E) 2.3 (95%CI 1.9–2.8, P < 0.001), and F) 1.9 (95%CI 1.1–2.7, P < 0.001). Bars represent mean and standard deviation. Abbreviation: CI, confidence interval.
Fig. 4.
Fig. 4.
Radiotherapy choice bases on extent of pelvic lymphadenectomy. Bars represent proportion and 95% confidence interval. Among women who received adjuvant radiotherapy, proportion of intracavitary brachytherapy (ICBT) and whole pelvic radiotherapy (WPRT) are shown based on sampled nodes for pelvic lymphadenectomy (LND): A) type I stage IA, B) type I stage IB, C) type I stage II, D) type II stage IA, E) type II stage IB, and F) type II stage II.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A, Cancer statistics, 2016, CA Cancer J. Clin 66 (2016) 7–30. - PubMed
    1. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ, Contemporary management of endometrial cancer, Lancet 379 (2012) 1352–1360. - PubMed
    1. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG, A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study, Gynecol. Oncol 92 (2004) 744–751. - PubMed
    1. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M, Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma, Lancet 355 (2000) 1404–1411. - PubMed
    1. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL, Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet 375 (2010)816–823. - PubMed

Publication types

MeSH terms

LinkOut - more resources